Petrigliano Frank A, Liu Nancy Q, Lee Siyoung, Tassey Jade, Sarkar Arijita, Lin Yucheng, Li Liangliang, Yu Yifan, Geng Dawei, Zhang Jiankang, Shkhyan Ruzanna, Bogdanov Jacob, Van Handel Ben, Ferguson Gabriel B, Lee Youngjoo, Hinderer Svenja, Tseng Kuo-Chang, Kavanaugh Aaron, Crump J Gage, Pyle April D, Schenke-Layland Katja, Billi Fabrizio, Wang Liming, Lieberman Jay, Hurtig Mark, Evseenko Denis
Department of Orthopaedic Surgery, Keck School of Medicine of USC, University of Southern California (USC), Los Angeles, CA, 90033, USA.
Department of Orthopaedic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.
NPJ Regen Med. 2021 Nov 23;6(1):77. doi: 10.1038/s41536-021-00187-3.
Osteoarthritis (OA) impacts hundreds of millions of people worldwide, with those affected incurring significant physical and financial burdens. Injuries such as focal defects to the articular surface are a major contributing risk factor for the development of OA. Current cartilage repair strategies are moderately effective at reducing pain but often replace damaged tissue with biomechanically inferior fibrocartilage. Here we describe the development, transcriptomic ontogenetic characterization and quality assessment at the single cell level, as well as the scaled manufacturing of an allogeneic human pluripotent stem cell-derived articular chondrocyte formulation that exhibits long-term functional repair of porcine articular cartilage. These results define a new potential clinical paradigm for articular cartilage repair and mitigation of the associated risk of OA.
骨关节炎（OA）影响着全球数亿人，患者承受着巨大的身体和经济负担。诸如关节表面局灶性缺损之类的损伤是OA发生的主要危险因素。目前的软骨修复策略在减轻疼痛方面有一定效果，但通常用生物力学性能较差的纤维软骨替代受损组织。在此，我们描述了一种同种异体人多能干细胞来源的关节软骨细胞制剂的开发、单细胞水平的转录组个体发育特征及质量评估，以及规模化生产，该制剂可对猪关节软骨进行长期功能性修复。这些结果为关节软骨修复及降低OA相关风险确定了一种新的潜在临床模式。
